ArticleHereditas2026
Tussilagone mitigates sepsis-induced acute lung injury in mice by suppressing RIPK1 expression.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveSepsis is a severe condition characterized by life-threatening organ dysfunction resulting from an excessive host response to infection. Among the affected organs, the lungs are particularly susceptible during the progression of sepsis. Tussilagone (TS), a sesquiterpenoid compound derived from the flowers of Tussilago farfara, has been explored for its potential therapeutic effects on sepsis-induced lung injury. This study used both in vitro and in vivo experimental approaches, complemented by network pharmacology analyses, to verify the mechanisms and molecular targets underlying the effects of TS.
methodsTS was administered to mice with sepsis-induced lung injury and to lung epithelial cells stimulated with lipopolysaccharide (LPS) to assess its therapeutic potential. Inflammatory factor levels in mouse serum, lung tissue, and cells were assessed. Western blot analysis was used to determine the expression of NF-κB p65 and MyD88 in lung tissues. Potential molecular TS targets were identified, with receptor-interacting serine/threonine-protein kinase 1 (RIPK1) selected for further investigation using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Additionally, the study explored if TS exerts its protective effects against lung injury in septic mice through targeted regulation of RIPK1.
resultsTS inhibited the NF-κB p65 and MyD88 signaling pathways, reducing the release of inflammatory factors and a mitigation of lung injury severity in LPS-induced MLE12 cells and CLP-induced septic mice. Overexpression of RIPK1 protein resulted in elevated expression levels of NF-κB p65 and MyD88, whereas treatment with TS significantly reduced these levels. Similarly, the use of a RIPK1 protein inhibitor to suppress RIPK1 expression also decreased the expression of NF-κB p65 and MyD88, further supporting the role of RIPK1 in the mechanism of TS-mediated lung protection.
conclusionTS demonstrates a protective effect against sepsis-induced acute lung injury (ALI) by inhibiting the expression of RIPK1. These findings indicate that TS can potentially be a therapeutic agent for the treatment of ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.